PSYCHOTROPIC DRUGS

Psychotropic drugs constitute a heterogeneous group of pharmacological agents that modulatecentral nervous system activity to alter mood, cognition, behavior, and perception. Their clinicalutility spans a wide spectrum of psychiatric and neurological disorders, including majordepressive disorder, schizophrenia, bipolar affective disorder, anxiety disorders, and sleepdisturbances. These agents are pharmacologically classified into antidepressants, antipsychotics,mood stabilizers, anxiolytics, and hypnotics. Their therapeutic effects are primarily mediatedthrough modulation of key neurotransmitter systems—particularly serotonin, dopamine,norepinephrine, and gamma-aminobutyric acid (GABA)—via receptor binding, reuptakeinhibition, or enzymatic regulation.Recent developments in psychopharmacology have focused on enhancing receptor selectivity,reducing adverse effect profiles, and improving patient adherence. Despite their proven efficacy,psychotropic drugs are associated with a spectrum of adverse events, including metabolic,cardiovascular, and neurological complications, necessitating individualized treatmentstrategies and ongoing clinical monitoring. Emerging evidence also highlights the role ofpharmacogenomics in predicting treatment response and optimizing drug selection. Thisevolving field underscores the importance of evidence-based prescribing practices andintegrated therapeutic approaches to achieve optimal clinical outcomes.Keywords:Psychotropic drugs, neurotransmitters, psychopharmacology,antidepressants, antipsychotics,mood stabilizers, anxiolytics, pharmacogenomics, clinical monitoring, psychiatric disorders.